Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Lung connection may explain survival advantage in Parasite-Linked hypertension

NCT ID NCT07707193

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at how well the right side of the heart works with the lungs in people who have high blood pressure in their lung arteries caused by schistosomiasis, a parasitic infection common in parts of Africa and South America. Researchers will use echocardiography to measure a key ratio called TAPSE/PASP, which reflects how efficiently the heart pumps blood against the increased pressure. The goal is to understand why some patients with this condition tend to live longer than those with other forms of pulmonary hypertension.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help explain why some patients with schistosomiasis-related pulmonary hypertension live longer than those with other forms of the disease.
What could go wrong
This is an observational study with only 50 participants, so findings may not apply to all patients. It measures heart function but does not test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients above 18 year diagnosed with schistozomiasis through history of exposure , serology , positive stool antigens ,Symmers' periportal fibrosis (the "clay pipe-stem" appearance) or Splenomegaly and suspected pulmonary hypertension through Probability Score" approach based on the 2022 ESC/ERS Exclusion Criteria: * All patients below 18 years old. * Left ventricular systolic or diastolic dysfunction. * Significant left-sided valvular heart disease. * severe chronic lung disease such as, Chronic obstructive pulmonary disease (COPD) ---- GOLD 4 and severe Interstitial lung disease (ILD). * Chronic Thromboembolic Pulmonary Hypertension. * Congenital heart diseases. * Severe hepatic or renal impairment unrelated to schistosomiasis. * Hemodynamically unstable patients. * Poor echocardiographic window preventing adequate RV assessment. * Active infection or acute systemic illness. * Refusal to participate in the study. * Significant arrhythmias affecting hemodynamic assessment (e.g., uncontrolled atrial fibrillation). * Previous heart or lung transplantation. * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schistosomiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension schistosomiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schistosomiasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mansoura university hospitals

    Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.